VALENSCION

Pharmaceuticals for use in the treatment of viral infection, bacterial infection, asthma, allergies, cancer, transplant rejection, inflammatory diseases and disorders, immune diseases and disorders, hereditary diseases and disorders, namely, metabolic, endocrine, neurologic and cardiovascular diseases or disorders, and auto immune diseases and disorders; pharmaceuticals for use in the treatment of T-cell and B-cell leukemias and lymphomas; medical therapeutic preparations, namely, biologically active modulators, biologically active immune modulators, biologically active antisense DNA or RNA compounds, chemical modulators of gene expression working at DNA transcription, RNA or translation processes; immunomodulatory oligonucleotides, namely, ingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; medical therapeutic preparations, namely, small molecule chemicals aimed at inhibiting cellular proteins

Medical research; scientific research; biological research; chemical research; pharmaceutical research services; pharmaceutical research and development; product research and development; medical and scientific research in the area of oligonucleotides or chemical products; medical and scientific research in the area of the structure-based drug design; biological and chemical research in the field of immunology, virology, oncology and hereditary diseases; medical and scientific research in the area of small molecule chemicals aimed at inhibiting cellular proteins for use as therapeutic agents; pharmaceutical research and development in the field of infectious diseases and disorders, cancer, viral diseases and disorders, inflammatory diseases and disorders, immunological diseases and disorders, autoimmune diseases and disorders, hereditary diseases and disorders, and cardiovascular diseases and disorders